SCHEMBL1246426

SCHEMBL1246426

S=C=NCCC(c1ccccc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MIF P14174 8/20 0.53
TRPA1 O75762 2/20 0.53
CYP2E1 P05181 1/20 0.53
CYP2A6 P11509 1/20 0.53
HIF1A Q16665 1/20 0.53
CYP2A13 Q16696 1/20 0.53
EPAS1 Q99814 1/20 0.53
NAAA Q02083 4/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP3A4 P08684 1/20 0.47
HPGD P15428 1/20 0.47
HRH1 P35367 4/20 0.45
KEAP1 Q14145 2/20 0.42
NFE2L2 Q16236 2/20 0.42
HTR2A P28223 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8987415 0.80 MIF (0.46) MIFTRPA1CYP2E1CYP2A6HIF1A
SCHEMBL1247842 0.79 HRH1 (0.45) ALDH1A1CYP3A4HRH1HTR2A
SCHEMBL1247579 0.78 MIF (0.50) MIFTRPA1CYP2E1CYP2A6HIF1A
SCHEMBL14216820 0.76 HRH1 (0.50) ALDH1A1CYP3A4HRH1HTR2A
SCHEMBL8101646 0.74 MIF (0.57) MIFTRPA1CYP2E1CYP2A6HIF1A
Hydrochloric Acid SCHEMBL28151898 0.74 HRH1 (0.48) ALDH1A1CYP3A4HRH1HTR2A
SCHEMBL8763999 0.72 MIF (0.48) MIFTRPA1CYP2E1CYP2A6HIF1A
SCHEMBL8101546 0.72 MIF (0.54) MIFTRPA1CYP2E1CYP2A6HIF1A
SCHEMBL9957097 0.72 MIF (0.55) MIFTRPA1CYP2E1CYP2A6HIF1A
SCHEMBL29028764 0.71 HRH1 (0.50) ALDH1A1CYP3A4HRH1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708255-B2 (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders Casero, Robert A. (US) 2017-07-18 US disclosed
US-20120322877-A1 (BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-12-20 US disclosed
EP-2467359-A2 (BIS) UREA AND (BIS) THIOUREA COMPOUNDS AS EPIGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS The Johns Hopkins University (US) 2012-06-27 EP disclosed
WO-2011022489-A2 (BIS) UREA AND (BIS) THIOUREA COMPOUNDS AS EPIGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322877-A1 (BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS KDM4A, KDM1A, EHMT1 MIF 4685/4885TRPA1 3987/4885CYP2E1 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.